Sperm chromatin structure components are differentially repaired in cancer survivors

Journal of Andrology

Volumn 33, Issue 4, 2012, Pages 629-636

  O'flaherty, Cristian M ^a   Chan, Peter T ^a,b   Hales, Barbara F ^a   Robaire, Bernard ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

DNA strand breaks; Nuclear compaction; Protamines; Thiol groups

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOBIMANE; CHROMOMYCIN A3; DNA; THIOL DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHROMATIN STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA COMPACTION; DNA DAMAGE; DNA DETERMINATION; DNA REPAIR; DNA STRAND BREAKAGE; DRUG INDUCED DISEASE; HODGKIN DISEASE; HUMAN; MALE; MALE INFERTILITY; PRIORITY JOURNAL; SEMEN ANALYSIS; SIDE EFFECT; SPERM; SPERM CHROMATIN QUALITY; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY; TESTIS CANCER;

ADULT; ANTINEOPLASTIC AGENTS; CHROMATIN; CHROMOMYCIN A3; DNA DAMAGE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; SEMEN ANALYSIS; SPERMATOZOA; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 84866412919     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.015388     Document Type: Article

References (44)

1. Bedford JM, Bent MJ, Calvin H. Variations in the structural character and stability of the nuclear chromatin in morphologically normal human spermatozoa. J Reprod Fertil. 1973; 33:19-29.
2. Bieber AM, Marcon L, Hales BF, Robaire B. Effects of chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility. J Androl. 2006; 27:189-200.
3. Bizzaro D, Manicardi GC, Bianchi PG, Bianchi U, Mariethoz E, Sakkas D. In-situ competition between protamine and fluorochromes for sperm DNA. Mol Hum Reprod. 1998; 4:127-132.
4. Bjorndahl L, Kvist U. Human sperm chromatin stabilization: a proposed model including zinc bridges. Mol Hum Reprod. 2009; 16: 23-29.
5. Castillo J, Simon L, De Mateo S, Lewis S, Oliva R. Protamine/DNA ratios and DNA damage in native and density gradient centrifuged sperm from infertile patients. J Androl. 2011; 32:324-332.
6. Clermont Y. Kinetics of spermatogenesis in mammals: seminiferous epithelium cycle and spermatogonial renewal. Physiol Rev. 1972; 52:198-236.
7. Delbes G, Hales BF, Robaire B. Effects of the chemotherapy cocktail used to treat testicular cancer on sperm chromatin integrity. J Androl. 2007; 28:241-249.
8. Delbes G, Vaisheva F, Luu T, Marcon L, Hales BF, Robaire B. Reversibility of the effects of the chemotherapeutic regimen for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone, on the male rat reproductive system and progeny outcome. Reprod Toxicol. 2010; 29:332-338.
9. Evenson DP, Jost LK, Marshall D, Zinaman MJ, Clegg E, Purvis K, De Angelis P, Claussen OP. Utility of the sperm chromatin structure assay as a diagnostic and prognostic tool in the human fertility clinic. Hum Reprod. 1999; 14:1039-1049.
10. Evenson DP, Larson KL, Jost LK. Sperm chromatin structure assay: its clinical use for detecting sperm DNA fragmentation in male infertility and comparisons with other techniques. J Androl. 2002; 23:25-43.
11. Evenson D, Wixon R. Meta-analysis of sperm DNA fragmentation using the sperm chromatin structure assay. Reprod Biomed Online. 2006; 12:466-472.
12. Fossa SD, De Angelis P, Kraggerud SM, Evenson D, Theodorsen L, Clausen OP. Prediction of posttreatment spermatogenesis in patients with testicular cancer by flow cytometric sperm chromatin structure assay. Cytometry. 1997;30:192-196.
13. Gandini L, Sgro P, Lombardo F, Paoli D, Culasso F, Toselli L, Tsamatropoulos P, Lenzi A. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod. 2006; 21:2882-2889.
14. Gao XL, Mirau P, Patel DJ. Structure refinement of the chromomycin dimer-DNA oligomer complex in solution. J Mol Biol. 1992; 223:259-279.
15. Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol. 1999; 17:1493-1498.
16. Huddart RA, Birtle AJ. Recent advances in the treatment of testicular cancer. Expert Rev Anticancer Ther. 2005; 5:123-138.
17. Kopp HG, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, Bamberg M, Hartmann JT. Advances in the treatment of testicular cancer. Drugs. 2006; 66:641-659.
18. Kvist U, Björndahl L, Kjellberg S. Sperm nuclear zinc, chromatin stability, and male fertility. Scanning Microsc. 1987; 1:1241-1247.
19. Marchetti F, Wyrobek AJ. Mechanisms and consequences of paternally-transmitted chromosomal abnormalities. Birth Defects Res C Embryo Today. 2005; 75:112-129.
20. Marcon L, Hales BF, Robaire B. Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat. J Androl. 2008; 29:408-417.
21. Marcon L, Zhang X, Hales BF, Nagano MC, Robaire B. Development of a short-term fluorescence-based assay to assess the toxicity of anticancer drugs on rat stem/progenitor spermatogonia in vitro. Biol Reprod. 2010; 83:228-237.
22. Marcon L, Zhang X, Hales BF, Robaire B, Nagano MC. Effects of chemotherapeutic agents for testicular cancer on rat spermatogonial stem/progenitor cells. J Androl. 2011; 32:432-443.
23. Meistrich ML, Finch M, Da Cunha MF, Hacker U, Au WW. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res. 1982; 42:122-131.
24. Mocchegiani E, Paolucci P, Granchi D, Cavallazzi L, Santarelli L, Fabris N. Plasma zinc level and thymic hormone activity in young cancer patients. Blood. 1994; 83:749-757.
25. O'Flaherty C, Hales BF, Chan P, Robaire B. Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity. Fertil Steril. 2010; 94:1374-1379.
26. O'Flaherty C, Vaisheva F, Hales BF, Chan P, Robaire B. Characterization of sperm chromatin quality in testicular cancer and Hodgkin's lymphoma patients prior to chemotherapy. Hum Reprod. 2008; 23:1044-1052.
27. Payne JF, Raburn DJ, Couchman GM, Price TM, Jamison MG, Walmer DK. Redefining the relationship between sperm deoxyribonucleic acid fragmentation as measured by the sperm chromatin structure assay and outcomes of assisted reproductive techniques. Fertil Steril. 2005; 84:356-364.
28. Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol. 1999; 10:1475-1483.
29. Pogach LM, Lee Y, Gould S, Giglio W, Meyenhofer M, Huang HF. Characterization of cis-platinum-induced Sertoli cell dysfunction in rodents. Toxicol Appl Pharmacol. 1989; 98:350-361.
30. Prasad AS, Beck FW, Snell DC, Kucuk O. Zinc in cancer prevention. Nutr Cancer. 2009; 61:879-887.
31. Sawhney P, Giammona CJ, Meistrich ML, Richburg JH. Cisplatininduced long-term failure of spermatogenesis in adult C57/Bl/6J mice. J Androl. 2005; 26:136-145.
32. Smit M, Van Casteren NJ, Wildhagen MF, Romijn JC, Dohle GR. Sperm DNA integrity in cancer patients before and after cytotoxic treatment. Hum Reprod. 2010; 25:1877-1883.
33. Spano M, Bonde JP, Hjollund HI, Kolstad HA, Cordelli E, Leter G. Sperm chromatin damage impairs human fertility. The Danish First Pregnancy Planner Study Team. Fertil Steril. 2000; 73:43-50.
34. Spermon JR, Ramos L, Wetzels AM, Sweep CG, Braat DD, Kiemeney LA, Witjes JA. Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer. Hum Reprod. 2006; 21:1781-1786.
35. Stahl O, Eberhard J, Jepson K, Spano M, Cwikiel M, Cavallin-Stahl E, Giwercman A. The impact of testicular carcinoma and its treatment on sperm DNA integrity. Cancer. 2004; 100:1137-1144.
36. Tempest HG, Ko E, Chan P, Robaire B, Rademaker A, Martin RH. Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin lymphoma patients. Hum Reprod. 2007; 23:251-258.
37. Theis B, Nishri D, Bahl S, Bahl S, Marrett L. Cancer in young adults in Canada [Internet]. Toronto, Canada: Cancer Care Ontario; 2006 May, ISBN 0-921325-11-8 (pdf). Available from: http://www.phacaspc.gc.ca/publicat/cyac-cjac06/index-eng.php. Last modification of this page was September 11, 2006.
38. Vaisheva F, Delbes G, Hales BF, Robaire B. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome. J Androl. 2007; 28:578-587.
39. Virro MR, Larson-Cook KL, Evenson DP. Sperm chromatin structure assay (SCSA) parameters are related to fertilization, blastocyst development, and ongoing pregnancy in in vitro fertilization and intracytoplasmic sperm injection cycles. Fertil Steril. 2004; 81: 1289-1295.
40. World Health Organisation (WHO). WHO Laboratory Manual for Examination of Human Semen and Semen-Cervical Mucus Interaction. Cambridge, United Kingdom: Cambridge University Press; 1999: 1-20.
41. Wykes SM, Krawetz SA. The structural organization of sperm chromatin. J Biol Chem. 2003; 278:29471-29477.
42. Zini A, Boman JM, Belzile E, Ciampi A. Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: systematic review and meta-analysis. Hum Reprod. 2008; 23:2663-2668.
43. Zini A, Mak V, Phang D, Jarvi K. Potential adverse effect of semen processing on human sperm deoxyribonucleic acid integrity. Fertil Steril. 1999; 72:496-499.
44. Zubkova EV, Wade M, Robaire B. Changes in spermatozoal chromatin packaging and susceptibility to oxidative challenge during aging. Fertil Steril. 2005; 84:1191-1198.